This article first appeared on GuruFocus .
Release Date: August 06, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
CytomX Therapeutics Inc ( NASDAQ:CTMX ) is aggressively advancing its lead asset, Varetta M, a first-in-class EPCAM-targeting ADC, with a clear path toward a registrational study in late-line colorectal cancer (CRC) by the first half of 2027.
-
The company is broadening Varetta M's potential by initiating phase 1 expansion cohorts in additional GI cancers (gastric, pancreatic, and biliary tract), positioning it as a potential pan-tumor therapy.
-
Strong clinical progress is highlighted by preliminary PFS data of 6.8-7.1 months at the top two doses in late-line CRC, which compares favorably to existing benchmarks of 4.5-5.5 months for standard of care.
-
The company has a solid financial runway, projecting cash to last until at least the second half of 2028, which supports advancing Varetta M through key clinical milestones.
-
The expanded collaboration with Regeneron, including a $37 million payment, validates CytomX's proprietary masking technology and provides additional non-dilutive funding.
-
The company is strengthening its leadership team with key appointments in regulatory affairs, legal, and a new board member with deep GI oncology expertise, preparing for late-stage development.
Negative Points
-
Total revenue decreased significantly to $1.4 million in Q2 2026 from $18.7 million in Q2 2025, due to the conclusion of major collaborations with BMS and Aelis.
-
Operating expenses increased to $25.2 million in Q2 2026 from $19.9 million in Q2 2025, driven by higher R&D costs for manufacturing and personnel, which could pressure future cash flow.
-
The company faces a key safety risk with Varetta M, as the rate of grade 3 diarrhea is a concern; while initial prophylaxis data is encouraging, the acceptable threshold is up to 20%, which could limit its use in earlier lines of therapy.
-
The development strategy for the first registrational study is still undecided (third vs. fourth line), and the company is awaiting more mature data, including overall survival, to make a final decision.
-
The company is enrolling unselected patients in CRC but will need to screen for EPCAM expression in pancreatic and biliary tract cancers, which could slow enrollment and limit the addressable patient population in those indications.
-
The initial data for the bevacizumab combination and the new phase 1/2 trial in second-line CRC will not be available until the first half of 2027, leaving a significant gap in clinical updates.
Q & A Highlights
Q: What is the bar for success or a good outcome on median PFS for the monotherapy readout, and what are your thoughts on the control arm for the registrational study? Would the FDA require Lonsurf plus Bev as a comparator? A: Sean McCarthy (CEO): We plan to communicate data when we have an initial read on PFS for the optimization cohorts, which were fully enrolled by the end of April. Our baseline assumption for the first registrational study is that the primary endpoint will be overall survival. In the fourth line, the most likely comparator would be fruquintinib or regorafenib, or perhaps Physician's Choice. In the third line, we assume the comparator would most likely be bevacizumab plus Lonsurf. For benchmarks, fourth-line monotherapy treatments have response rates of 1-2%, a few months of PFS, and 5-6 months of OS. With Bev plus Lonsurf in the third line, PFS is 4.5-5.5 months and OS is 9-10 months. We previously reported preliminary PFS of 6.8-7.1 months at the TOP2 doses (8.6 and 10 mg/kg), which we are very encouraged by.
Q: Could you comment on how you're approaching dose selection for the new GI cancer expansion cohorts and the bevacizumab combination study in colorectal cancer? Are you utilizing the same prophylaxis strategy? A: Sean McCarthy (CEO): We are excited to move into additional GI indications with Varetta M, as EPCAM is expressed in these and many other solid tumors. Dose selection for the monotherapy cohorts is informed by the escalation, expansion, and optimization work done in colorectal cancer. For the bevacizumab combination, we are exploring Q2 week and Q4 week schedules to align with bevacizumab's clinical schedule. We started at meaningful doses of Varetta M rather than going back to the beginning of dose escalation. We are on track to present initial data in the first half of next year. Yes, we are utilizing the same loperamide and budesonide prophylaxis strategy in the Bev combo study.
Q: What do you see as the path forward for the combo studies in earlier-line CRC, and when could we expect data? What are the potential requirements for future studies? A: Sean McCarthy (CEO): The bevacizumab combination is foundational given how integral Bev is across multiple lines of CRC treatment. It will open up opportunities for a potential third-line study and enable work in first and second-line settings over time. We are also excited to start the chemo combination with 5-FU later this year, designed to bring Varetta M into the second line to replace irinotecan, where FOLFIRI is most commonly used. It's too early to comment on potential registrational paths in earlier lines, but these combination studies unlock enormous potential in the coming years.
Q: With the $37 million payment from Regeneron received in Q3, would that be recognized fully in revenues in the third quarter? A: Chris Ogden (CFO): We are thrilled to expand the collaboration with Regeneron, which reflects the foundational science. The $37 million payment is for two additional programs, taking our pro forma cash to about $367 million. This payment will be recognized as we do the work and make progress. Since these are preclinical projects, we expect the recognition to play out over a few years at least.
Q: There is a fear that if the grade 3 diarrhea rate is on the higher end of the 10-20% range in the year-end update, there could be a risk to moving the product upstream. How would you respond to this pushback? A: Sean McCarthy (CEO): We are highly focused on this area as we move through the monotherapy dose optimization cohorts. In our March data update, the prophylaxis strategy of loperamide and budesonide was very encouraging, bringing the grade 3 diarrhea rate down to 10%. The 20% number is what we've been discussing, but it's all about risk-benefit. Given the high unmet need in late-line and even second-line CRC, and the impressive activity we've seen with Varetta M, we believe the risk-benefit profile will be favorable. We will continue to learn about the etiology, time to onset, and impact of prophylaxis to manage this adverse event over time.
Q: Are you targeting a certain amount of follow-up time for the CRC late-line update by year-end, given that the study was enrolled in April? Also, what are your thoughts on EPCAM expression levels in biliary tract and pancreatic ductal cancer? A: Sean McCarthy (CEO): For the next update, we are working towards an update across the entire 113-patient study, including data from the 40 patients in dose optimization. Our goal is to communicate data when it is sufficiently mature to have a preliminary estimate of progression-free survival. We will also provide the first look at overall survival from the escalation and expansion phases, which will be foundational for our decision on the first pivotal study. Regarding EPCAM expression, it is expressed at some level in just about all patients. EPCAM-high patients are about 50-60% in pancreatic and biliary tract cancers. We plan to screen for EPCAM expression in these tumor types as a starting point, though we haven't disclosed the cutoff yet. In gastric and GEJ cancer, we expect to enroll an unselected population given the high percentage of EPCAM-expressing tumors.
Q: As you get closer to the year-end update and the planned registration start in the first half of next year, what pieces of the puzzle are becoming clearer? Have you met with the FDA, and what needs to be resolved before finalizing the registration population and endpoints? A: Sean McCarthy (CEO): We are very focused on this question and anticipate multiple interactions with the FDA across the program in the back half of 2026. We continue to see tremendous opportunity in either the fourth-line or third-line settings. We need to pin down what those patient populations look like, the relevant comparator arm in each, and as data matures, the sizing of those studies. We will make a data-driven decision, take our recommendations to the FDA, and move forward with the first pivotal study in the first half of next year. Everything remains on track.
Q: How are you approaching prior irinotecan or prior TOP1 inhibitor exposure in the non-CRC cohorts? A: Sean McCarthy (CEO): In the late-line patients treated to date across the phase 1 study, everyone has seen irinotecan over their treatment journey, which is
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
